Inolimomab
Inolimomab is a mouse monoclonal antibody developed as an immunosuppressive drug against graft-versus-host disease. Its target is the alpha chain of the interleukin-2 receptor.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD25 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
  | |
References
- Piñana JL, Valcárcel D, Martino R, et al. (November 2006). "Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease". Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. 12 (11): 1135–41. doi:10.1016/j.bbmt.2006.06.010. PMID 17085306.
- Dartois, C.; Freyer, G.; Michallet, M.; Hénin, E.; You, B.; Darlavoix, I.; Vermot-Desroches, C.; Tranchand, B.; Girard, P. (2007). "Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease". Clinical Pharmacokinetics. 46 (5): 417–432. doi:10.2165/00003088-200746050-00004. PMC 2760126. PMID 17465640.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.